Global Trust Asset Management LLC Decreases Stock Position in Eli Lilly and Company (NYSE:LLY)

Global Trust Asset Management LLC trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,643 shares of the company’s stock after selling 25 shares during the quarter. Global Trust Asset Management LLC’s holdings in Eli Lilly and Company were worth $1,268,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the business. Advisory Alpha LLC grew its stake in Eli Lilly and Company by 3.7% in the 4th quarter. Advisory Alpha LLC now owns 3,751 shares of the company’s stock worth $2,896,000 after acquiring an additional 133 shares in the last quarter. West Branch Capital LLC grew its stake in Eli Lilly and Company by 13.6% in the 4th quarter. West Branch Capital LLC now owns 5,124 shares of the company’s stock worth $3,956,000 after acquiring an additional 612 shares in the last quarter. Missouri Trust & Investment Co grew its stake in Eli Lilly and Company by 4.8% in the 4th quarter. Missouri Trust & Investment Co now owns 1,082 shares of the company’s stock worth $835,000 after acquiring an additional 50 shares in the last quarter. XML Financial LLC grew its stake in Eli Lilly and Company by 2.8% in the 4th quarter. XML Financial LLC now owns 1,825 shares of the company’s stock worth $1,409,000 after acquiring an additional 50 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its stake in Eli Lilly and Company by 12.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 262,358 shares of the company’s stock worth $202,540,000 after acquiring an additional 28,024 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the sale, the chief accounting officer now owns 5,480 shares in the company, valued at approximately $4,402,522.40. This represents a 14.11 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 0.13% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

LLY has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. StockNews.com upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday. Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. Barclays dropped their price objective on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research note on Thursday, October 31st. Finally, Truist Financial increased their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. Four investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $1,002.22.

Eli Lilly and Company Trading Up 1.6 %

NYSE LLY opened at $766.00 on Friday. The company has a fifty day simple moving average of $776.31 and a two-hundred day simple moving average of $850.93. The stock has a market cap of $727.18 billion, a P/E ratio of 82.81, a P/E/G ratio of 1.56 and a beta of 0.41. Eli Lilly and Company has a 12-month low of $624.68 and a 12-month high of $972.53. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business had revenue of $11.44 billion for the quarter, compared to analysts’ expectations of $12.09 billion. During the same period last year, the business earned $0.10 EPS. The company’s revenue for the quarter was up 20.4% on a year-over-year basis. On average, analysts forecast that Eli Lilly and Company will post 12.98 earnings per share for the current year.

Eli Lilly and Company declared that its board has initiated a stock repurchase plan on Monday, December 9th that permits the company to repurchase $15.00 billion in shares. This repurchase authorization permits the company to repurchase up to 2% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.78%. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is 56.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.